Highest-materiality recent filing
Alaunos reports ALN1003 preclinical data: -12.9% weight loss, liver weight -43%; cash only $0.35M
ALN1003 in DIO mice: mean body weight change -12.9% by Day 33 and -10.3% by Day 48 (p<0.0001).
Alaunos announces preclinical ALN1003 data; cash only $0.354M, runway into Q2 2026
ALN1003 showed significantly lower HOMA-IR (p=0.0006) and higher adiponectin-to-leptin ratio in DIO mouse models.
Alaunos Therapeutics receives Nasdaq delisting notice for equity shortfall; 45 days to submit plan
Nasdaq notified Alaunos on April 9, 2026, of non-compliance with minimum $2.5M stockholders' equity; 2025 10-K reported $2.153M.
Alaunos reports positive preclinical data for ALN1003; weight loss up to 12.9% in DIO mice
ALN1003 showed dose-dependent body weight loss: -12.9% peak (Day 34) and -10.3% after 48 days vs DIO control (p<0.0001).
Alaunos reports positive preclinical obesity data but cash runway only through Q1 2026
Preclinical DIO mouse study shows statistically significant dose-related weight loss and improved body composition; lead compound identified.
Alaunos regains Nasdaq compliance after reporting $3.66M equity in Q2 2025
Nasdaq notified Alaunos of compliance on August 19, 2025, following prior stockholders' equity deficiency.
Alaunos shareholders approve 10x increase in authorized common shares, reverse split authorization
Stockholders approved increasing authorized common shares from 5M to 50M; amendment effective July 10, 2025.
Dale Curtis Hogue Jr. resigned as CEO and director effective July 1, 2025; no disagreement.
Alaunos Therapeutics raises $850K via private placement of Series A-2 Convertible Preferred Stock
Aggregate purchase price of $850,000 from accredited investors; offering closed June 24, 2025.
Alaunos Therapeutics raises ~$2.05M in registered direct offering of stock and pre-funded warrants
338,725 shares at $3.36; 271,674 pre-funded warrants at $3.359/share.
Alaunos Therapeutics enters $25M equity purchase agreement with Mast Hill Fund
Mast Hill commits to buy up to $25M of common stock over 24 months at Company's discretion.
Alaunos receives Nasdaq deficiency notice for equity below $2.5M minimum; 45 days to submit plan
Stockholders' equity of $2.063M as of Dec 31, 2024, falls short of Nasdaq's $2.5M minimum under Rule 5550(b)(1).
Terminated Amended and Restated License Agreement with Precigen effective Oct 4, 2024; Sleeping Beauty patent expiry in 2026 cited.
Alaunos Therapeutics to effect 1-for-10 reverse stock split on July 17, 2024
Board approved 1-for-10 reverse split; authorized by shareholders on June 6, 2024.
Alaunos shareholders approve reverse stock split (1:5-1:15) and authorized share increase to 50M
Stockholders approved reverse stock split at ratio between 1-for-5 and 1-for-15, at Board's discretion, effective June 12, 2024.
Alaunos Therapeutics regains Nasdaq minimum bid price compliance; panel monitor for one year
Nasdaq notified Alaunos on Feb 16, 2024 that it has regained compliance with the $1.00 bid price requirement.
Alaunos Therapeutics effects 1-for-15 reverse stock split effective Jan 31, 2024
Reverse stock split at a ratio of 1-for-15, effective January 31, 2024 at 5:00 p.m. ET.
Alaunos appoints new director, cash runway into Q3 2024, plans reverse stock split
Dale Curtis Hogue, Jr. appointed independent director effective Dec 29, 2023; receives initial 150k option grant vesting over 36 months.
CEO Kevin S. Boyle terminated effective Dec 22, 2023; separation payment ~$331,990 (six months base salary + COBRA).
Alaunos terminates SVP Legal and VP R&D; execs receive separation payments, consulting
Melinda Lackey (SVP, Legal) and Drew Deniger (VP, R&D) terminated without cause, effective Nov 15, 2023.
Alaunos receives Nasdaq delisting notice; Q3 net loss $8.5M; exploring strategic alternatives
Nasdaq determined to delist TCRT because bid price was below $0.10 for 10 consecutive days; suspension effective Nov 17, 2023.
Alaunos Therapeutics winds down TCR-T trial, cuts workforce 60%, explores strategic alternatives
Q2 2023 net loss $8.8M ($0.04 per share); cash $18.3M, expected to fund ops into Q4 2023.
Transfer of Common Stock listing from Nasdaq Global Select to Capital Market approved July 5, effective July 7, 2023.
Alaunos Therapeutics stockholders approve reverse stock split and increase in authorized shares
Stockholders approved a reverse stock split at a ratio of 1-for-5 to 1-for-15, at Board discretion (141.4M for, 38.5M against).
Alaunos Q1 net loss $10M; debt-free after SVB loan prepayment; expects interim TCR-T data Q3
Net loss of $10.0M ($0.04/share) vs $9.8M ($0.05) in Q1 2022; R&D expenses up 17% to $6.5M.
Third Amendment to Loan & Security Agreement, effective March 30, 2023.
Alaunos Therapeutics receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Alaunos on Jan 4, 2023 that TCRT bid price closed below $1.00 for 30 consecutive business days.
Alaunos Therapeutics prices $15.7M public offering of 24.2M shares at $0.62/share
Priced 24,228,719 shares at $0.6191 per share for gross proceeds of $15.7M.
Alaunos reports Q3 net loss $8.9M; first objective response in TCR-T Library trial
Q3 2022 net loss $8.9M ($0.04/sh) vs $22.7M ($0.11/sh) in Q3 2021; revenue $2.9M from darinaparsin milestone.
Robert Hofmeister, Ph.D. Resignation On April 15, 2025, Dr. Hofmeister resigned as a member of the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect.
On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, of Alaunos Therapeutics, Inc. (the "Company"), effective February 23, 2024.
On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement (the “Consulting Agreement”), effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s Vice President, Finance.
On January 20, 2024, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer of the Company, effective January 20, 2024.
On December 29, 2023, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as a director of the Company, effective immediately.
Pursuant to the terms of his employment agreement, upon his termination Mr. Boyle was deemed to automatically resign from the Company’s board of directors.
On December 22, 2023, Alaunos Therapeutics, Inc. (the “Company”) entered into a Separation and Release Agreement, effective December 22, 2023, with Kevin S. Boyle, Sr. (the “Separation Agreement”), the Company’s Chief Executive Officer, in connection with Mr. Boyle’s termination.
On December 18, 2023, Mary Thistle resigned as a member of the board of directors of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect.
the Company terminated the employment of Melinda Lackey, Senior Vice President, Legal and Administration
With Mr. Huang’s departure, the Board has elected Holger Weis as the Company’s new Chairman of the Board.
On September 22, 2023, James Huang resigned as Chairman and member of the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect in order to focus on other business pursuits.
Christopher Bowden, M.D. delivered notice of his resignation from the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”), effective March 30, 2023.
Max materiality 0.85 · Median 0.60 · Most common event other_material